https://bccr.tums.ac.ir/index.php/bccrj/issue/feed 2024-10-12T08:42:05+0330 Dr. Kazem Zendehdel, Editor-in-Chief bccr@tums.ac.ir Open Journal Systems https://bccr.tums.ac.ir/index.php/bccrj/article/view/544 2024-10-12T08:42:05+0330 Saba Mirzaei smirzaeii1994@gmail.com Mahdieh Salimi salimi@nigeb.ac.ir Hossein Mozdarani mozdarani@modares.ac.ir

<p><strong>Background: </strong>Breast cancer is the leading cause of death for women worldwide. Optimal methods for most cancer control require the use of appropriate biomarkers. Recently, circular RNAs (circRNAs), as closed-loop RNA molecules generated through reverse splicing, have emerged as promising biomarkers for cancer development.</p> <p><strong>&nbsp;Methods:</strong> In this observation, the expression of 3 unique circRNAs - cdr1as, circRNA-000284, circ-ITCH - within the peripheral blood of breast cancer patients was studied using Real-Time RT-PCR before and after chemotherapy compared with the control. &nbsp;</p> <p><strong>Results:</strong> The data confirmed that the analyzed circRNAs expression was significantly altered in breast cancer patients compared to the controls. These alterations have been related to advanced stages, lymph node involvement, and metastasis. CircRNA-000284 expression considerably decreased after chemotherapy. This may proposed its potential as a biomarker for monitoring treatment response.</p> <p><strong>Conclusion:</strong> These findings provide valuable insights for the development of novel</p> <p>&nbsp;strategies in the management and treatment of breast cancer. However, further studies are required to validate the clinical utility of these circRNAs as biomarkers and to explore their underlying mechanisms in breast cancer progression<strong>.</strong></p>

2024-10-12T08:42:05+0330 ##submission.copyrightStatement## https://bccr.tums.ac.ir/index.php/bccrj/article/view/500 2024-10-12T08:38:16+0330 Nemali Deepthi Deepthi Priya nemalideepthi39@gmail.com NANDA KUMAR K V feelnandu@gmail.com DEVARAJAPPAGARI BINDU bindhuhimabindhu0@gmail.com KASIREDDY LIKHITHA LIKITHAKASIREDDY25@GMAIL.COM MEKALA SIVA CHARANI CHARANICHARRI@GMAIL.COM

<p>Uterine cancer is the most prevalent gynecological malignancy in developed and developing countries and its incidence is arising every year. Worldwide, approximately 382,000 new cases are diagnosed each year and there are an estimated 90,000 deaths. &nbsp;As endometrial cancer becomes more prominent, the need to develop and characterize biomarkers for early-stage diagnosis and the treatment. We analyze the current state of biomarker utilization for early detection, including their sensitivity and specificity, paving the way for timely interventions. Several biomarkers, including P53, K-RAS, CA-125, HER2/neu, HE4, PTEN, MSI are used for early detection, treatment, and prevention of uterine cancer. Prognostic biomarkers in uterine cancer have emerged as indispensable tools for predicting disease progression and patient outcomes. Endometrial biopsy, CT scan, MRI Scan, Dilation and Curettage, Transvaginal ultrasound are vital for diagnosing and staging of uterine cancer and provide essential information about the cancer’s presence, size, and spread, guiding proper treatment decisions. Various treatments modalities, including surgery, Chemotherapy, targeted therapies are examined. In conclusion, early detection through biomarkers like P53, K-RAS, HER2/neu, PTEN, Serum CA-125 holds great promise for early diagnosis and treatment advancements, and offering hope for improved outcomes and a better quality of life for patients in the future.</p>

2024-10-12T00:00:00+0330 ##submission.copyrightStatement##